HPV16 E6 DNA疫苗诱导小鼠抗宫颈癌主动免疫

目的：探讨HPV16 E6 DNA疫苗能否在体内诱导小鼠抗宫颈癌主动免疫应答。 方法：将HPV16 E6基因转染615小鼠宫颈癌U14，建立高表达E6的U14细胞株即E6+U14；制备HPV16 E6 DNA疫苗；随后分组进行体内预防和治疗E6+U14移植同系小鼠试验，设立对照组；观察各组小鼠肿瘤大小，计算抑瘤率、生存时间；计算淋巴和肺转移率；体外分别检测经HPV16 E6 DNA疫苗免疫后的小鼠T 淋巴细胞对E6+U14和U14的杀伤作用。结果：HPV16 E6 DNA疫苗预防和治疗组小鼠各时期瘤体大小均显著低于对照组（均P<0.001 ），两组抑瘤率均大于70%；平均生存时间均大于对照组（均P<0.001）；预防组淋巴转移率低于对照组（P<0.05）；HPV16 E6 DNA疫苗免疫小鼠T淋巴细胞在不同效靶比，对E6+U14的杀伤效率均明显高于对U14者（均P<0.001）。结论：HPV16 E6 DNA疫苗能诱导机体产生针对HPV16 E6阳性的宫颈癌细胞主动免疫应答及特异性细胞毒淋巴细胞，提示该疫苗可能对临床治疗宫颈癌有效。     

人乳头瘤病毒16型E7抗原表达模型的构建

目的 :构建pEGFP HPV1 6E7表达载体 ,并观察其在肝癌细胞中的瞬时和稳定表达及小鼠肝癌细胞皮下成瘤情况 ,为建立表达HPV1 6E7的实体瘤动物模型奠定基础。方法 :应用基因重组技术 ,构建增强绿色荧光蛋白(EGFP)与HPV1 6E7的融合表达载体 ,经限制性内切酶酶切鉴定和PCR分析 ,用脂质体转染技术将其转入小鼠肝癌细胞 ,2 4h后RT PCR检测HPV1 6E7mRNA的生成 ,荧光显微镜观察EGFP HPV1 6E7融合蛋白的表达 ,将转染细胞接种小鼠皮下 ,观察成瘤及成瘤后融合蛋白的表达情况。结果 :酶切鉴定和PCR分析证实重组质粒中插入目的基因片段及载体DNA大小、方向和插入位点均正确 ,在转染的小鼠肝癌细胞中检测到HPV1 6E7mRNA的生成和绿色荧光蛋白的表达 ,接种的转染细胞在小鼠皮下可成瘤且可检测到HPV1 6E7mRNA的生成。结论 :pEGFP HPV1 6E7表达载体便于观察转染细胞中EGFP HPV1 6E7融合蛋白的表达情况 ,小鼠肝癌细胞接种小鼠皮下可成瘤 ,成瘤后可检测到HPV1 6E7mRNA的转录     

人胃癌移植瘤演进过程中肥大细胞的研究

目的 :为了探讨肥大细胞与肿瘤演进的关系。方法 :将冻存的人胃低分化粘液腺癌MGC 80 3细胞悬液先在裸小鼠皮下接种成瘤 ,瘤直径 1cm时取完整瘤组织块再分别接种到裸小鼠的皮下、胃壁上至成瘤。分早 (2 0d以内 )、中 (2 0～ 4 0d)、晚 (40d以上 )三期观察皮下和胃壁移植肿瘤的侵袭转移情况并用甲苯胺蓝染色法检测肥大细胞。结果 :皮下、胃壁移植瘤都只在晚期才出现转移 ,皮下组肺转移率 57 1%(4/ 7) ,胃壁组肺、肝、胃周淋巴结转移率皆为 50 0 %(3/ 6 ) ,并广泛扩散至肠、脾、肝、肾等处。正常皮下组织和皮下移植瘤早、中、晚三期肥大细胞数目分别为 18.77± 8.6 0 ,4 .30± 5.4 9,5.50± 3.86和 2 .6 7± 2 .2 8,正常胃壁和胃壁移植瘤早、中、晚三期肥大细胞数目分别为 12 .6 3± 4 .4 7,6 .0 3± 3.11,3.59± 1.6 9和 1.97± 2 .13,两组肥大细胞数目基本上为依次递减(P <0 .0 1)。结论 :肥大细胞在肿瘤侵袭转移过程中可能有一定的抑制作用。     

人α-甘露糖苷酶Man2c1转基因对移植性肿瘤在小鼠体内生长和转移的影响

目的研究人α-甘露糖苷酶(hMan2c1)转基因对小鼠移植性肿瘤生长、转移的影响。方法接种肝癌细胞H22或肉瘤细胞S180于野生型ICR小鼠和3个系的转基因小鼠(28、35和54号)右侧腋窝皮下,连续测量肿瘤体积。分别于接种细胞第9天和第10天处死小鼠,称重肿瘤。分别对肿瘤组织和肺组织进行HE染色。用Tris-NH4Cl破碎脾脏中的红细胞,以Yac-1细胞为靶细胞,检测脾脏中自然杀伤(NK)细胞的活性。结果接种于3个系的转基因小鼠的H22肿瘤或S180肿瘤的体积及重量均显著高于野生型小鼠(P<0.05)。绝大多数转基因小鼠的肿瘤向周围组织侵袭,而野生型小鼠的肿瘤几乎均有包膜。54、35和28号转基因小鼠的H22肿瘤肺转移率分别为30%(3/10)、50%(5/10)和30%(3/10),野生型小鼠的肿瘤肺转移率为10%(1/10);54、35和28号转基因小鼠的S180肿瘤肺转移率分别为16.7%(1/6)、50%(3/6)和33.3%(2/6),野生型小鼠的肿瘤肺转移率为0(0/10)。转基因小鼠脾脏的NK细胞活性与野生型小鼠比较差异无显著性(P>0.05)。结论hMan2c1转基因促进移植性H22肿瘤及S180肿瘤在ICR小鼠的生长、侵袭和转移,hMan2c1转基因对小鼠脾脏NK细胞的活性无影响。     

肿瘤转移抑制基因KAI1在宫颈癌的表达及其与HPV感染的关系

目的探讨肿瘤转移抑制基因KAI1在宫颈癌中的蛋白表达以及人乳头瘤病毒(HPV)16E6、E7和HPV18E6/E7感染对其表达的影响。方法采用免疫组化SP法检测70例浸润性宫颈癌、15例原位癌、20例正常宫颈组织中KAI1蛋白的表达,采用PCR扩增-琼脂糖凝胶电泳法检测浸润性宫颈癌组织中HPV16E6、E7和HPV18E6/E7的DNA状况。结果宫颈浸润癌及原位癌组织中的KAI1蛋白表达与正常宫颈上皮中的表达相比明显下调(P<0.05),原位癌与浸润癌中的表达差异无统计学意义;HPV16E6、E7和HPV18E6/E7在浸润性宫颈癌中的阳性率分别为67.1%、54.3%和12.9%,HPV16E6、E7和HPV18E6/E7感染与宫颈癌中的KAI1蛋白表达无相关性。结论肿瘤转移抑制基因KAI1在宫颈癌中呈下调表达,HPV16E6、E7和HPV18E6/E7感染不影响其表达。     

RNA干涉抑制宫颈癌HPV16 E6基因的研究

目的采用RNA干涉（RNAi）技术干扰宫颈癌HPV16 E6基因转录，通过体外和体内实验了解其特异性抑制HPV16 E6基因的效率。方法设计合成针对HPV16 E6的小干扰RNA（siRNA），借脂质体转染宫颈癌CaSki细胞，通过测定转染后不同时间点的细胞凋亡率、HPV16 E6mRNA及蛋白表达变化了解基因抑制的效率。体内实验中建立子宫颈癌荷瘤裸鼠模型，将E6 siRNA直接注入瘤体，观察肿瘤体积的变化，肿瘤切片HPV16 E6免疫组化染色，观察肿瘤坏死和细胞的凋亡。结果HPV16 E6siRNA转染细胞后24h、48h、5d和9d时凋亡率分别为7．7％、11．8％、37．4％和12．6％。RT-PCR显示转染后24h、48h、5d和9d HPV16 E6 mRNA量减少了77％、83％、59％和41％。Western blot显示转染后的HPV16 E6蛋白表达在24h、48h、5d明显减少，9d时有所恢复；流式细胞仪HPV16 E6蛋白定量测定结果显示，转染后24h、48h、5d和9d蛋白表达抑制率分别为79．7％、80．4％、71．3％和57．4％。体内实验瘤内注射HPV16 E6 siRNA明显抑制肿瘤的生长，HPV16 E6蛋白表达明显受抑，肿瘤组织坏死和细胞凋亡增加，重复给药较单次给药效果更好。结论体内和体外实验均表明RNA干涉HPV16 E6基因的效果具有特异性和高效性。     

CD44v6、E-Cadherin表达与CNE-2Z-F1裸鼠移植瘤转移的关系

目的　探讨CD44v6、E -Cadherin表达与人鼻咽癌裸鼠移植瘤转移的关系。方法　分别将人鼻咽癌细胞克隆株F1在体外与鼠肺块共同孵育及胸内移植 ,然后将带瘤细胞肺块 (Ⅰ组 )和胸内瘤组织块 (Ⅱ组 )各行裸鼠皮下移植 ,并与瘤细胞悬液皮下移植瘤 (Ⅲ组 )比较 ,观察各组移植瘤转移特点。采用免疫组织化学技术检测各组移植瘤回复培养细胞CD44v6和E -Cadherin表达。结果　Ⅰ组和Ⅱ组皮下移植瘤的总转移率和淋巴结转移率均高于Ⅲ组 (其中ⅠvsⅢ ,P <0 .0 5) ;肺转移仅发生在Ⅰ组。这两组移植瘤细胞CD44v6表达水平明显增高 ,其阳性细胞数分别为 (79.7± 5.7) %、(74.1± 3.1 ) % ,第 3组为 (65.6± 4.31 ) %移植瘤转移率与CD44v6高表达密切相关 ;E -Cadherin阳性细胞分别为 (41 .7± 4.9) %、(43.8± 6.4) %和 (2 7.4± 4.9) % ,Ⅰ组、Ⅱ组与Ⅲ组之间比较 ,有显著差异 (P <0 .0 5)。结论　CD44v6的过表达和E -Cadherin功能障碍 ,可能在鼻咽癌侵袭转移中起一定作用。     

RNA干扰技术抑制HPV16 E6基因表达对宫颈癌细胞株CaSki增殖的影响

目的观察HPV16 E6小干扰RNA(siRNA)能否抑制宫颈癌细胞生长,并探讨其作用机理。方法化学合成针对HPV16 E6的siRNA,借脂质体转染宫颈癌CaSki细胞,应用细胞计数的方法测定细胞生长曲线、活细胞率及细胞生长抑制率。运用实时荧光定量RT-PCR、流式细胞术检测转染后不同时间点细胞周期、HPV16 E6、p53、p21 mRNA及蛋白表达的变化。结果转染HPV16 E6 siRNA后,细胞生长明显受到抑制。流式细胞术结果显示并未将细胞阻滞在G1期。实时荧光定量RT-PCR显示,转染24h,E6 mRNA的表达比空白组降低了20.11倍(P<0.05),而p53、p21 mRNA的表达无明显变化。转染48h,E6蛋白表达明显下调,Pp53、P21蛋白表达相应地升高。结论HPV16 E6 siRNA可通过特异、高效地沉默宫颈癌细胞E6mRNA的表达,减少对野生型p53的降解,恢复P53蛋白的功能活性而发挥抑制宫颈癌细胞生长的作用。     

RNA干扰HPV E6下调eIF4E转录表达抑制宫颈癌Hela细胞增殖并影响细胞周期进程研究

目的探讨宫颈癌Hella细胞中干扰HPV E6对eIF4E表达的调控,探寻HPV E6促癌的新途径,为宫颈癌诊断和治疗提供新靶点。方法构建高效的靶向HPV18 E6的shRNA质粒(shE6)并测序,而后转染人宫颈癌Hela细胞,荧光显微镜及流式细胞术检测转染效率。而后以Real-time PCR检测E6及eIF4E的mRNA水平,采用CCK-8法检测Hela细胞增殖能力的改变,流式细胞术检测细胞周期。结果测序结果显示成功构建shE6质粒。shE6-3转染人宫颈癌Hela细胞后48 h,E6及eIF4E mRNA表达的抑制率分别约为80%,76%。shE6-3对Hela细胞的增殖活性在48 h的抑制效果最明显,增殖抑制率约为21%;相对于NC组,shE6组G0/G1期细胞比例显著增高,而S期比例减少,G2/M期未见明显变化。结论 RNA干扰HPV E6能够下调eIF4E转录表达,抑制宫颈癌Hela细胞增殖,并阻滞细胞周期于G0/G1期。eIF4E有望成为宫颈癌防治的潜在靶点。     

HPV DNA、HPV E6/E7蛋白和TCT在宫颈上皮内瘤变及宫颈癌筛查中的价值

目的 探讨人乳头瘤病毒（human papilloma virus,HPV） DNA、HPV E6/E7蛋白和液基薄层细胞学检查（thin-prep cytology test,TCT）在宫颈上皮内瘤变（cervical intraepithelial neoplasia,CIN）及宫颈癌筛查中的价值。方法 选取2021年7月至2022年6月于诸暨市人民医院妇科接受早期宫颈癌筛查的成年女性190例为研究对象,分别进行HPV DNA、HPV E6/E7蛋白及TCT检测,并进一步行阴道镜活检检查。比较不同病变患者的HPV DNA、HPV E6/E7蛋白和TCT对高级别病变的诊断效能。结果 CIN3及宫颈癌患者的HPV DNA、HPV E6/E7蛋白、TCT检查及三者联合检测的阳性率均显著高于宫颈炎患者（P<0.05）,宫颈癌患者的HPV DNA、HPV E6/E7蛋白、TCT检查及三者联合检测的阳性率均显著高于CIN1患者（P<0.05）。CIN2+患者的HPV DNA、HPV E6/E7蛋白、TCT及三者联合检测的阳性率显著高于CIN1–患者。HPV DNA、HPV E6/E7蛋白、TCT三者联合诊断高级别病变的敏感度、特异性、阳性预测值和阴性预测值分别为90.80%、30.10%、52.32%、79.48%。结论 HPV DNA、HPV E6/E7蛋白及TCT可作为筛查宫颈癌和癌前病变的手段,且三者联合检测的敏感度最高。     

转染人乳头瘤病毒的宫颈癌U14移植同系小鼠后的生长特征和转移规律

OBJECTIVE: To investigate the growth behavior and metastatic pattern of murine cervix cancer U14 transfected with human papillomavirus(HPV) in inbred 615-strain mouse. METHODS: We transfected HPV 16 E6 and E7 genes into mouse cervix carcinoma cell strain NO. 14(U14) by electroporation and liposome, respectively. The transfectants were selected by G418, and several high-expressed HPV16 E6 and E7 clonal cell lines (E6+ U14, E7+ U14) were detected by PCR and by immunohistochemistry. We transplanted those cells into inbred 615-strain mice both subcutaneously and intraperitoneally to observe the growth behavior and metastasis of them. RESULTS: The durations of tumor appearance were 5-7 d, 11-14 d, and 8-10 d after having been transplanted subcutaneously with wild type U14, E6+ U14, and E7+ U14, respectively(P < 0.05). The mean survival times of mice were 29 d, 43 d, and 35 d, respectively. Metastasis could be found both in lymph nodes (90%, 30%, and 40%, respectively) and lungs (60%, 10%, and 20%, respectively). After intraperitoneal inoculation, the mean survival durations of mice were 14.2 d, 20.6 d and 18.3 d. We could not find metastasis both in lymph nodes and lungs. CONCLUSION: Murine cervix cancer U14 cells transfected with HPV16 E6 and E7 have different growth behavior and metastatic patterns after transplanted in inbred mice, which provide useful models for studying their immunotherapy or other strategies for cervical cancer with E6 and E7 as a target.     

Therapeutic antitumor response to cervical cancer in mice immunized with U14 v accines transfected with costimulatory B7 gene

Objective To investigate the effect of U14 vaccine transfected with the B7 gene in inducin g antitumor immune response to murine cervical carcinoma in Chinese 615-strain mice.Methods A recombinant retroviral plasmid vector expressing mouse B7-1 gene (pLNSX-mB7) was transfected into 615-strain mouse cervical carcinoma cell line No. 14 (U1 4) by electroporation to set up a highly-expressed mB7-1 U14 cell clonal strai n (B7(+)U14). In vivo experiments: (1) B7(+)U14 vaccine was primed to protect t he 615-strain mice against U14 re-challenge. (2) B7(+)U14 vaccine was injecte d into tumor-bearing mice with different tumor sizes. Lifetimes and tumor s izes were recorded. In vitro cytotoxicity assay: Mice were immunized with B 7(+)U14 or U14 vaccine and 2 weeks later, spleen cells of those mice were cultur ed for 2 days. The cytotoxicity of these cells against U14 was detected by 5-d iphenyl tetrazolium bromide assay.Results We obtained several B7-1 high expression clonal U14 lines. In vivo experiment, we did not find tumor growing in 3 of the 6 mice primed by B7(+)U14 vaccine during their entire life after re-challenge with U14. The other 3 mice develo ped tumors and their average survival time was longer than that of the control g roup (P&lt;0.01). All 6 mice grew tumors in the control group. When the transplanted tumors became palpable, the mice were randomly divided into 3 group s to be injected with B7(+)U14 vaccine. It was effective for tumor-bearing mic e only when the tumor diameters were &lt;3 mm. When the diameters were ≥3 mm, it was not efficacious to inject B7(+)U14 vaccine (P&lt;0.05). In vitro cytotoxicity assay, cytotoxic T lymphocytes induced by B7(+)U14 vaccine h ad a high er cytotoxicity against U14 than that induced by U14 vaccine (F=310.8, P &lt;0.001).Conclusions Vaccines of cervical cancer cells transfected with the costimulatory molecule B7 gene can induce antitumor immune protection in host mice against U14 re-challe nge. This treatment may cure part of the tumor-bearing mice but be restricted by tumor size. The results suggest that transfecting the B7 gene into cervical cancer as a cell vaccine may be an efficient supplementary method to treat cervi cal cancer after operation.     

人乳头状瘤病毒与促癌物协同作用诱发人胚宫颈细胞恶性转化研究

目的：研究人乳头状瘤病毒（HPV）与促癌物协同作用在scid小鼠体内诱发人胚宫颈细胞的恶性转化。方法：包装制备含HPV16E6E7逆转录病毒,感染人胚宫颈细胞,按分组将所需细胞移植于scid小鼠右侧肩部皮下,共分4组：实验组为感染病毒的宫颈细胞 亚精胺 正丁酸组,共7只;病毒组为感染病毒的宫颈细胞组,共5只;促癌组为正常宫颈细胞 亚精胺 正丁酸组,共5只;对照组为正常宫颈细胞组,共4只。按实验要求于移植第3日起在小鼠左侧肩部皮下注射亚精胺和正丁酸,每周1次。观察12周后处死动物,如发生肿瘤,则对瘤组织行病理诊断,并作PCR检测HPV16E6E7基因。结果：实验组成瘤比例5/7,其他3组成瘤率皆为0,实验组肿瘤的病理学检查证实为肉瘤,应用PCR方法在肿瘤组织中检测到HPV16E6E7基因。结论：宫颈细胞在感染含HPV16E6E7基因的逆转录病毒后,在亚精胺和正丁酸协同作用下发生恶性转化。     

Relationship between invasion and metastasis of tumor cells.

This work was done to examine the relationship between invasion and metastasis of different types of tumor cells. Three kinds of tumor cells were studied: a mouse uterine cervix carcinoma (U14) with high metastatic potential; a human nasopharyngeal carcinoma (CNE-2Z) with high metastatic potential; and a human uterine cervix carcinoma (CC801) with low metastatic potential. CNE-2Z and CC801 were implanted subcutaneously in the footpads and subcapsularly in the testes of nude mice, respectively. U14 was implanted both in the footpads and subcapsularly in the testes of inbred 615-strain mice. With each of these animal models, the extent of tumor invasion could be divided into grades I-IV. The metastasis of tumor cells was found to depend upon: 1) the malignant characteristics of the tumor cells; 2) the degree of local invasion; 3) the presence of tumor cells in the lymphatic ducts and blood vessels; and 4) the organ specificity of metastatic development. Metastasis was most often found when invasion reached a high degree (grades III to IV).     

瘤体注射表皮生长因子受体抗体治疗小鼠宫颈癌

目的 :观察阻断表皮生长因子受体是否治疗小鼠宫颈癌。方法 :将小鼠宫颈癌细胞U14(1× 10 7)移植入近交系 6 15系小鼠皮下 ,待成瘤后将 2 4只小鼠随机分为 4组 ,用表皮生长因子受体单克隆抗体 (EGFR -McAb)瘤体局部注射 (每天 1次 ,连续 2周 )治疗A和B组 ,用生理盐水对照治疗对照A和对照B组。观察治疗A及对照A组小鼠的生存期和肿瘤的抑瘤率。并取治疗后第 4,7,10 ,14,16 ,17d处死的治疗B组及对照B组小鼠瘤体组织作血管内皮标记物CD31免疫组化染色 ,计算肿瘤内平均微血管密度。结果 :用EGFR -McAb治疗A组平均生存期 42 .8d ,较对照组 2 8.3d明显延长 (P <0 .0 1)。治疗A组肿瘤抑瘤率第 4d为 13% ,第 7d为 42 % ,第 10～ 14d达高峰 ,维持在 83% 84%。第 7,10 ,14d治疗A组与对照A组瘤体体积差异显著 (P <0 .0 5 )。治疗组肿瘤内微血管密度明显低于对照组(P <0 .0 5 )。结论 :EGFR -McAb可有效治疗小鼠宫颈癌 ,提示其可作为宫颈癌导向治疗的候选靶分子。     

Induction of SiHa Cells Cells Apoptosis by Nanometer Realgar Suspension and Its Mechanism

The effects of nanometer realgar suspension on proliferation and apoptosis of human uterine cervix cancer cell line SiHa cells and oncogenic genes HPV16E6/E7 were investigated. A "micro-jet efflux" strategy was used for the preparation of nanometer realgar suspension. SiHa cells were treated with nanometer Realgar suspension in various concentrations (6.25,12.5,25 and 50mg/L) for different durations (12,24,48 and 72h). The inhibitive effect of nanometer realgar suspension on growth of SiHa cells was detected by MIT method. Special morphological changes of apoptosis were observed by transmission electron microscopy (TEM) and DNA fragments electrophoresis. The apoptotic rate was quantified by flow cytometry (FCM). The expression of HPV16E6/E7 mRNA and protein was assayed by RT-PCR and Western blot respectively. The results showed after being treated with 25-50mg/L nanometer realgar suspension for 48h, the survival rate of SiHa cells was decreased, and apoptotic rate markedly increased in a time- and concentration-dependent manner. TEM and DNA electrophoresis revealed the special morphological changes of apoptosis. The apoptotic rate of SiHa cells treated with nanometer realgar suspension was significantly higher than in the control group (P<0.01), and G0/G1 phase arrest appeared following treatment with nanometer realgar suspension in 25 and 50mg/L for 48h.RT-PCR and Western blot assay indicated that nanometer realgar suspension reduced the HPV16E6/E7 gene expression. Nanometer realgar suspension could inhibit the proliferation and induce apoptosis of SiHa cells. The mechanism may be related to the down-regulation of the HPV16E6/E7 gene expression.     

人乳头瘤病毒16型E6/E7基因对人角质形成细胞增殖及其调控因子的影响

目的 研究人乳头瘤病毒（ＨＰＶ）１６型Ｅ６／Ｅ７基因对人角质形成细胞增殖及细胞周期调控因子ｐ５３,ｐＲｂ的影响。方法 Ｌｏｐｏｆｅｔａｍｉｎｅ介导法进行 染,筛选阳性克隆,免疫荧光染色检测ＨＰＶ１６Ｅ６／Ｅ７在转染细胞内的表达,流式细胞仪分析细胞周期变化,免疫印迹分析ｐ５３,ｐＲｂ表达情况。结果 免疫荧光染色检测见转染细胞内有ＨＰＶＥ６／Ｅ７表达,汉式细胞仪显示转染细胞Ｇ１期细胞为４９．２％比正常     

人乳头瘤病毒16型E6E7基因协同共激活分子B7-1基因免疫诱导的特异性免疫反应

目的利用突变修饰后的中国山东地方株人乳头瘤病毒16型(humanpapillomavirustype16,HPV16)E6E7融合基因(fmE6E7),研究治疗HPV16感染相关疾病的DNA疫苗,并进一步探索利用共激活分子B7-1基因,研究更加活化细胞免疫的加强疫苗。方法将用PCR法扩增获得fmE6E7基因插入真核表达质粒pVR1012中获得pVR1012-fmE6E7,瞬时转染Cos-7细胞,免疫荧光组织化学法检测证实其表达后,在C57BL/6小鼠肌肉内进行pVR1012-fmE6E7单独免疫,或与小鼠共激活分子B7-1基因真核表达质粒(pcDNA3.1-B7-1)联合免疫。51Cr释放法分析免疫小鼠的细胞毒性T淋巴细胞(cytotoxicTlymphocytes,CTL)活性,间接ELISA法检测小鼠血清中E7特异性抗体。用5×105个C3细胞皮下接种C57BL/6小鼠,分析小鼠体内诱发的特异性抗瘤免疫水平。结果修饰后的E6E7基因免疫可诱导机体产生特异的抗体反应和CTL反应,小鼠B7-1基因与fmE6E7联合免疫可显著提高特异性CTL活性,并可保护33%(2/6)的小鼠免受C3肿瘤细胞的攻击,而单独fmE6E7基因免疫则不能抑制C3瘤细胞的生长,联合B7-1基因免疫对诱发的抗体水平无加强作用。结论中国山东地方株E6E7融合基因可用于DNA疫苗的构建,B7-1基因协同免疫可提高疫苗的细胞免疫水平,利用B7-1基因作为HPV16DNA疫苗的协同因子具有重要价值。